研究代号 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-25. Numbers and descriptions here follow the published literature rather than marketing material.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
| Property | Value | Notes |
|---|---|---|
| 研究代号 | LY3437943 | 文献中常用的实验标识 |
| 药物类别 | 三重受体激动剂 | 靶向GLP-1、GIP与胰高血糖素受体 |
| 开发状态 | 后期临床研究 | 尚未获批上市 |
| 主要研究人群 | 肥胖与2型糖尿病 | 入组条件依试验方案而定 |
| 常见同义词 | 瑞他鲁肽；LY3437943 | 名称拼写可能因语言和出版物而异 |
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Two polymorphs of technetium trichloride exist, α- and β-TcCl3. The α polymorph is also denoted as Tc3Cl9. It adopts a confacial bioctahedral structure. It is prepared by treating the chloro-acetate Tc2(O2CCH3)4Cl2 with HCl. Like Re3Cl9, the structure of the α-polymorph consists of triangles with short M-M distances. β-TcCl3 features octahedral Tc centers, which are organized in pairs, as seen also for molybdenum trichloride. TcBr3 does not adopt the structure of either trichloride phase. Instead it has the structure of molybdenum tribromide, consisting of chains of confacial octahedra with alternating short and long Tc—Tc contacts. TcI3 has the same structure as the high temperature phase of TiI3, featuring chains of confacial octahedra with equal Tc—Tc contacts. Several anionic technetium halides are known. The binary tetrahalides can be converted to the hexahalides [TcX6]2− (X = F, Cl, Br, I), which adopt octahedral molecular geometry. More reduced halides form anionic clusters with Tc–Tc bonds. The situation is similar for the related elements of Mo, W, Re. These clusters have the nuclearity Tc4, Tc6, Tc8, and Tc13. The more stable Tc6 and Tc8 clusters have prism shapes where vertical pairs of Tc atoms are connected by triple bonds and the planar atoms by single bonds. Every technetium atom makes six bonds, and the remaining valence electrons can be saturated by one axial and two bridging ligand halogen atoms such as chlorine or bromine.
== Medical uses == Lobeglitazone is used to assist regulation of blood glucose level of diabetes mellitus type 2 patients. It can be used alone or in combination with metformin. Lobeglitazone was approved by the Ministry of Food and Drug Safety (Korea) in 2013, and the postmarketing surveillance is on progress until 2019.
=== Carbon metabolism === Clostridium scindens can anaerobically ferment several different carbon sources, including monosaccharides (fructose, galactose, glucose, mannose, ribose, and xylose), a disaccharide (lactose), and a couple of 2-sugar alcohols (dulcitol and sorbitol). Glucose metabolism takes the form of mixed acid fermentation, as the fermentation products include acetate, ethanol, and formate. In defined and minimal media, the preferred glucose fermentation product for C. scindens is ethanol, while the production of hydrogen, acetate, and formate significantly decreases during growth in minimal media.
Sources: en.wikipedia.org
The shadow exists as part of the unconscious mind and is composed of the traits individuals instinctively or consciously resist identifying as their own and would rather ignore, typically repressed ideas, weaknesses, desires, instincts, and shortcomings. Much of the shadow comes as a result of an individual's adaptation to cultural norms and expectations. Thus, this archetype not only consists of all the things deemed unacceptable by society but also those things that are not aligned with one's own personal morals and values. Jung argued that each person has a desire to keep their shadow hidden under what he called the moral complex (equivalent to Freud's super-ego) and that this is the impetus for humans to learn and maintain the values of our cultures. The shadow can often appear as a dark, wild, exotic figure in dreams or visions. Jung argues that the shadow plays a distinctive role in balancing one's overall psyche, the counter-balancing to consciousness—"where there is light, there must also be shadow". In order to truly grow as an individual, Jung believed that both the persona and shadow should be balanced. Without a well-developed shadow (often "shadow work", "integrating one's shadow"), an individual can become shallow and extremely preoccupied with the opinions of others; that is, a walking persona. Not wanting to look at their shadows directly, Jung argues, often results in psychological projection. Individuals project imagined attitudes onto others without awareness.
The Port of Dover is a cross-channel ferry, cruise terminal, maritime cargo and marina facility situated in Dover, Kent, south-east England. It is the nearest English port to France, at just 34 kilometres (21 mi) away, and is one of the world's busiest maritime passenger ports, with 11.7 million passengers, 2.6 million lorries, 2.2 million cars and motorcycles and 80,000 coaches passing through it in 2017, and with an annual turnover of £58.5 million a year. This compares with the nearby Channel Tunnel, the only fixed link between the island of Great Britain and the European mainland, which now handles an estimated 20 million passengers and 1.6 million trucks per year. The modern port facility features a large artificial harbour constructed behind stone piers and a defensive concrete breakwater. The port is divided into two main sections: the Eastern Docks serve as the main cross-channel ferry terminal, while the Western Docks contain a cruise ship terminal and a yacht marina along with cargo facilities. The Port of Dover has a long history and possesses several listed buildings and structures. The port is owned and operated by the Dover Harbour Board, a statutory corporation formed by royal charter in 1606 by King James I. Most of the board members of the Dover Harbour Board are appointees of the Department for Transport. The port has its own private police force, the Port of Dover Police. The current port traffic volumes and urban population categorise Dover as a Large-Port Town.
Palaces – indigenous American civilizations such as the Olmecs, Mayans, Zapotecs, Aztecs, Mixtecs, Moche, Toltecs, Inca, Chimú, Nazca and many more built elaborate palaces. The Mayan palace in Palenque is one of the best examples of Mayan palace architecture. Papaya – indigenous people residing around the Caribbean Sea and Mexico, such as the Mayans, domesticated papayas. Paper - the Maya used bark to make a type of bark paper called amate. Although it was extensively used during the Triple Alliance, its production was mostly banned by the Spanish after the conquest Parkas – the Inuit in the Arctic were the first peoples in the world to develop parkas. Parkas are great insulators, which protected the Inuit against the harsh Arctic winter. The pocket of air that was located within sewed caribou fur in a parka, protected a person against the brutal Arctic winter. Peanuts – indigenous Americans were the first peoples in the world to cultivate peanuts. Peanut butter – the Inca and Aztec processed ground roasted peanuts into a paste similar to peanut butter. Pemmican – indigenous Americans were the first to develop pemmican as a nutritious and high-energy food. Pepper – Mesoamericans were the first to cultivate peppers, including chili peppers of all types and sweet red, green, yellow, and all other colorful hues of non-chilli peppers. Petroleum use – Native Americans in present-day Pennsylvania, the Iroquois, lit petroleum which seeped from underground to fire ceremonial fires.
Sources: en.wikipedia.org
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。
司美格鲁肽主要靶向GLP-1受体，而瑞他鲁肽同时作用于GLP-1、GIP和胰高血糖素受体。这种三重机制旨在产生不同的代谢效应，但临床差异仍需头对头研究确认。
长期心血管结局、停药后维持效果、罕见不良事件和不同人群中的获益风险比尚未完全确定。完整三期数据和监管审评将影响结论。
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.